141 related articles for article (PubMed ID: 31620946)
21. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
Hershfield MS
Immunodeficiency; 1993; 4(1-4):93-7. PubMed ID: 8167743
[No Abstract] [Full Text] [Related]
23. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
[TBL] [Abstract][Full Text] [Related]
26. Normal IgH Repertoire Diversity in an Infant with ADA Deficiency After Gene Therapy.
Baloh CH; Borkar SA; Chang KF; Yao J; Hershfield MS; Parikh SH; Kohn DB; Goodenow MM; Sleasman JW; Yin L
J Clin Immunol; 2021 Oct; 41(7):1597-1606. PubMed ID: 34184208
[TBL] [Abstract][Full Text] [Related]
27. Homozygous Splice ADA2 Gene Mutation Causing ADA-2 Deficiency.
Chong-Neto HJ; Segundo GRS; Bandeira M; Chong-Silva DC; Rosário CS; Riedi CA; Hershfield MS; Ochs H; Torgerson T; Rosário NA
J Clin Immunol; 2019 Nov; 39(8):842-845. PubMed ID: 31617030
[No Abstract] [Full Text] [Related]
28. Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2.
Keino D; Kondoh K; Kim Y; Sudo A; Ohyama R; Morimoto M; Nihira H; Izawa K; Iwaki-Egawa S; Mori T; Kinoshita A
Scand J Rheumatol; 2021 May; 50(3):243-245. PubMed ID: 32720851
[No Abstract] [Full Text] [Related]
29. Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID).
Chakravarti VS; Borns P; Lobell J; Douglas SD
Pediatr Radiol; 1991; 21(6):447-8. PubMed ID: 1749685
[TBL] [Abstract][Full Text] [Related]
30. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.
Husain M; Grunebaum E; Naqvi A; Atkinson A; Ngan BY; Aiuti A; Roifman CM
J Pediatr; 2007 Jul; 151(1):93-5. PubMed ID: 17586199
[TBL] [Abstract][Full Text] [Related]
31. Neutropenia among patients with adenosine deaminase deficiency.
Kim VH; Pham-Huy A; Grunebaum E
J Allergy Clin Immunol; 2019 Jan; 143(1):403-405. PubMed ID: 29753815
[No Abstract] [Full Text] [Related]
32. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
Girault D; Le Deist F; Debré M; Pérignon JL; Herbelin C; Griscelli C; Sciudery D; Hershfield M; Fischer A
Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
[TBL] [Abstract][Full Text] [Related]
33. Severe combined immunodeficiency due to adenosine deaminase deficiency.
Hussain W; Batool A; Ahmed TA; Bashir MM
J Pak Med Assoc; 2012 Mar; 62(3):297-9. PubMed ID: 22764473
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Two Boys Suffering From Deficiency of Adenosine Deaminase Type 2 (DADA2) With TNF-Inhibitor Etanercept.
Krutzke S; Horneff G
J Clin Rheumatol; 2021 Dec; 27(8S):S509-S512. PubMed ID: 31651641
[No Abstract] [Full Text] [Related]
35. Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.
Kanegane H; Taneichi H; Nomura K; Wada T; Yachie A; Imai K; Ariga T; Santisteban I; Hershfield MS; Miyawaki T
Pediatr Transplant; 2013 Feb; 17(1):E29-32. PubMed ID: 22805442
[TBL] [Abstract][Full Text] [Related]
36. Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.
Liu P; Santisteban I; Burroughs LM; Ochs HD; Torgerson TR; Hershfield MS; Rawlings DJ; Scharenberg AM
Clin Immunol; 2009 Feb; 130(2):162-74. PubMed ID: 18952502
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of mutations in a cohort of UK patients with ADA deficient SCID: Segregation of genotypes with specific ethnicities.
Adams SP; Wilson M; Harb E; Fairbanks L; Xu-Bayford J; Brown L; Kearney L; Madkaikar M; Bobby Gaspar H
Clin Immunol; 2015 Dec; 161(2):174-9. PubMed ID: 26255240
[TBL] [Abstract][Full Text] [Related]
38. Non-infectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiency.
Booth C; Algar VE; Xu-Bayford J; Fairbanks L; Owens C; Gaspar HB
J Clin Immunol; 2012 Jun; 32(3):449-53. PubMed ID: 22350222
[TBL] [Abstract][Full Text] [Related]
39. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
Bory C; Boulieu R; Souillet G; Chantin C; Guibaud P; Hershfield MS
Adv Exp Med Biol; 1991; 309A():173-6. PubMed ID: 1789201
[No Abstract] [Full Text] [Related]
40. Deficiency of Adenosine Deaminase 2-a Monogenic Cause of Wunderlich Syndrome.
Patra PK; Mondal SK; Singhal M; Kumrah R; Jindal AK; Hershfield M; Singh S
J Clin Immunol; 2021 Oct; 41(7):1693-1695. PubMed ID: 34259954
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
